Viviana Negrón González, MD

Breast Surgery, Residency Program Director

Viviana Negrón González

Contact Info

  • viviana.negron@upr.edu
  • Department of Surgery
    School of Medicine
    Medical Sciences Campus
    Office A-923
  • 787-763-2440

Education

  • BS: Biology, Magna Cum Laude, UPR Río Piedras Campus, 1999
  • MD: Magna Cum Laude UPR School of Medicine, 2003
  • Residency: General Surgery, UPR-Affiliated Hospitals, 2008
  • Fellowship: Breast Surgical Oncology, MD Anderson Cancer Cancer, Houston, TX, 2009

Field of Study

Personal Statement

After completing my general surgery residency, I went on to complete a Breast Surgical Oncology Fellowship at MD Anderson Cancer Center.  Ever since returning to Puerto Rico, I have been fortunate to be part of the general surgery residency faculty at the Auxilio Mutuo general surgery rotation and the Carolina General Surgery rotation.  Since 2018 I have also been the Program Director.  My practice is limited to breast disease including benign, disease, and malignancy.  I am an advocate of multidisciplinary management for breast cancer patients.

Positions and Honors

Positions:

  1. Program Director, General Surgery Residency, 2018-currently.
  2. Associate Professor: University of Puerto Rico, School of Medicine, March 1, 2020-currently.
  3. Cancer Committee, Hospital Auxilio Mutuo 20I5-currently.

Honors:

  1. Corynne S. Uhl Award, MD Anderson Cancer Center   2009.

Research

  1. Experimental Therapeutics for metastatic and triple negative breast cancer- Collaborator, University of Puerto Rico, Medical Science Campus, currently.

Publications

  1. Negrón-Gonzalez, V, Oh J, Cristofanilli M, Babiera G. Inflammatory Breast Cance1. Ln: Kuerer’s Breast Surgical Oncology. 1st Edition. 2010.
  2. Pascual-Marrero A, García J, Negrón V, Méndez W. General Surgery Residency Program response plan to Hurricane Maria in Puerto Rico. American College of Surgeons Meeting 2018. Oral Presentation.
  3. Dominici L, Negron-Gonzalez V, Hunt KK, Valero V, Buzdar AU, Kuerer H. lncidence of Documented Eradication of Breast Cancer in Axillary Lymph node metastases in patients overexpressing human epidermal growth factor receptor 2 treated with neoadjuvant chemotherapy regimens including Tastuzumab. Cancer. April 2010.
  4. Rivera N, Cabanillas F, Lawrenson L, Negron V, Pavia 0, Bruno M, Echenique M, Pardo W, Santiago K. Results of a novel neoadjuvant chemotherapy (NAC) for breast cancer. Cancer Research 73 (24 Supplement): P3-14-17. March 2014.
  5. Giraldo-Jimenez M, Cabanillas F, Negron V, Echenique M, Mojica P., Santiago K, Marcial V, Vaquer R and Carlo-Vargas V. Triple negative breast cancer: a retrospective study of Hispanics residing in Puerto Rico. Puerto Rico Health Sciences Journal. 31 (2): 45-51. June 2012.
  6. Cotto M, Toro J, Carlo V, Bruno M, Pavia 0, Echenique M, Vaguer V, Negron V, Cabanillas F. Comparison of first course Pet scan against fourth -course MRI for early detection of poor responders to neoadjuvant chemotherapy (NAC) for breast cancer (BC). Journal of Clinical Oncology. 28 (15_suppl): 564-564. May 2010.
  7. Mayorga-Pérez, I., Mulero-Soto, P., Cruz-De La Rosa, K., Negrón-González, V., Hernandez-Rosa, J., Feneque-Gonzalez, J., Correa-Rivas, M., Abdul-Hadi, A. “Bilateral phyllodes tumor: Case report”, Journal of Pediatric Surgery Case Reports, Volume 101, Feb. 2024.
  8. Torres-Sanchez, A., Cruz-Colazo, A., Kentzara, O., Rovira, M., Negrón, V., Carlo, V. “Pharmacodynamic neomalors for Rac and Cdc42 inhibitor efficacy”. Abstract submitted American Association of Cancer Research Annual Conferences. San Diego, CA. 2024.